Lower 30- and 60-day mortality rates vs 7+31,a
30- and 60-day overall all-cause mortality in patients aged 60-75 (ITT population)1
- 9 patients each in the VYXEOS arm (6%) and control arm (6%) had a fatal adverse reaction on treatment or within 30 days of therapy that was not in the setting of progressive disease1
- 8 patients in the control arm (5%) died within 30 days of treatment due to progressive leukemia1
- Fatal adverse reactions in the VYXEOS arm included infection, CNS hemorrhage, and respiratory failure1
aCytarabine 100 mg/m2 and daunorubicin 60 mg/m2.
Prolonged time to neutrophil and platelet recovery with VYXEOS1
Time to recovery of absolute neutrophil count and platelets may be prolonged with VYXEOS and require additional monitoring1
Learn about managing side effects that can be associated with VYXEOS treatment